ICI Therapy and Hair Loss: A Rare but Impactful Side Effect
Immune checkpoint inhibitors (ICIs) have transformed cancer treatment, empowering the immune system to target tumors more effectively. But with this breakthrough comes a range of immune-related adverse events (irAEs), including cutaneous reactions like dermatitis, vitiligo – and alopecia.
Hair loss is a well-known concern for cancer patients, yet data on alopecia linked to ICI therapy remains sparse. A new systematic review of 19 studies sheds light on ICI-associated alopecia, revealing it as a rare but potentially permanent side effect. Among reported cases (n=26), hair loss typically emerged within the first year of treatment, with just over half of affected patients experiencing some regrowth after intervention.
As ICIs continue to reshape oncology, dermatologists play a crucial role in recognizing and managing these cutaneous irAEs. What do these findings mean for patient care? Dive into the full study in JDD to learn more.
